Channel synergies ACEA Biosciences operates under Agilent Technologies, unlocking channel synergies to cross-sell high-performance cell analysis platforms through Agilent's established life sciences customer base and global distribution network.

Real-time leadership ACEA's xCELLigence RTCA platform and NovoCyte flow cytometers enable real-time cell analysis for preclinical drug discovery, toxicology, and safety pharmacology, appealing to pharma, biotech, and CROs seeking faster decision-making and richer data. The installed base and publications foundation bolster credibility for reference sales.

Software upsell Existing software offerings such as xCELLigence RTCA Software Pro and NovoExpress indicate clear opportunities to upsell advanced analytics, automated workflows, and integrated data management to researchers already using ACEA platforms.

Immunotherapy focus Past partnerships with Cancer Research Institute and active involvement in cancer immunotherapy research create a sales opening for integrated workflows, assay kits, and data analysis services tailored to oncology researchers and immunotherapy programs.

Global service With more than 2,500 instruments globally deployed, there is a substantial opportunity to grow service contracts, parts, consumables, and training across regions through ACEA's existing footprint and support ecosystem.